Original language | English |
---|---|
Pages (from-to) | 67-67 |
Journal | Annals of Oncology |
Volume | 30 |
Publication status | Published - Apr 2019 |
RATIONALE 001: Tislelizumab (BGB-A317) 1 concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)
L. Paz-Ares, S. Senan, D. Planchard, L. Wang, A. Cheong, R. Slepetis, M. H. Nguyen, E. E. Vokes
Research output: Contribution to journal › Meeting Abstract › Academic